Strides Pharma Science Ltd reported strong Q2FY24 performance with revenues of ₹10,264m and EBITDA of ₹1,801m, achieving six consecutive quarters of growth and all-time high revenue and EBITDA. They are on track to achieve their FY24 outlook.